Cargando…

Long-Term Follow-up of Reduced Intensity Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia: Prognostic Model to Predict Outcome

CLL remains incurable with chemoimmunotherapy, and allogeneic hematopoietic stem cell transplantation (HSCT) offers potential for cure. We assessed the outcomes of 108 CLL patients undergoing first allogeneic HSCTs, 76 with reduced intensity (RIC) and 32 with myeloablative (MAC) conditioning between...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brown, Jennifer R., Kim, Haesook T., Armand, Philippe, Cutler, Corey, Fisher, David C., Ho, Vincent, Koreth, John, Ritz, Jerome, Wu, Catherine, Antin, Joseph H., Soiffer, Robert J., Gribben, John G., Alyea, Edwin P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3519975/ https://www.ncbi.nlm.nih.gov/pubmed/22955330 http://dx.doi.org/10.1038/leu.2012.228

Ejemplares similares

Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation
por: Kekre, Natasha, et al.
Publicado: (2017)

Allogeneic hematopoietic cell transplantation outcomes in patients with Richter’s transformation
por: Kim, Haesook T., et al.
Publicado: (2021)

Favorable outcomes following allogeneic transplantation in adults with hemophagocytic lymphohistiocytosis
por: Gooptu, Mahasweta, et al.
Publicado: (2022)

(90)Y-Ibritumomab tiuxetan followed by reduced-intensity conditioning and allogeneic stem-cell transplantation in patients with advanced follicular lymphoma
por: Abou-Nassar, Karim E., et al.
Publicado: (2011)

Lower incidence of chronic GVHD observed after transplantation with cryopreserved unrelated allogeneic stem cells
por: Maurer, Katie, et al.
Publicado: (2023)

Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease
por: Kim, Haesook T., et al.
Publicado: (2022)

GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial
por: Ho, Vincent T., et al.
Publicado: (2022)

Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results
por: Koreth, John, et al.
Publicado: (2018)

Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution
por: Maurer, Katie, et al.
Publicado: (2021)

A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease
por: Whangbo, Jennifer S., et al.
Publicado: (2022)

Phenotypic and functional characterization of the CD6-ALCAM T-cell co-stimulatory pathway after allogeneic cell transplantation
por: Rambaldi, Benedetta, et al.
Publicado: (2022)

Posttransplant cyclophosphamide vs tacrolimus–based GVHD prophylaxis: lower incidence of relapse and chronic GVHD
por: Maurer, Katie, et al.
Publicado: (2023)

Fit Older Adults with Advanced Myelodysplastic Syndromes: Who is Most Likely to Benefit from Transplant?
por: Abel, Gregory A., et al.
Publicado: (2020)

Defibrotide: real-world management of veno-occlusive disease/sinusoidal obstructive syndrome after stem cell transplant
por: Nauffal, Mary, et al.
Publicado: (2022)

Cytokine release syndrome in haploidentical stem cell transplant may impact T-cell recovery and relapse
por: Shapiro, Roman M., et al.
Publicado: (2023)

Minor Histocompatibility Antigen DBY Elicits a Coordinated B and T Cell Response after Allogeneic Stem Cell Transplantation
por: Zorn, Emmanuel, et al.
Publicado: (2004)

COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience
por: Maurer, Katie, et al.
Publicado: (2021)

IL-7 and SCF Levels Inversely Correlate with T Cell Reconstitution and Clinical Outcomes after Cord Blood Transplantation in Adults
por: Politikos, Ioannis, et al.
Publicado: (2015)

Durability of clinical and immunologic responses to extended low-dose interleukin-2 therapy in patients with refractory chronic graft-versus-host disease
por: Donato, Veronica, et al.
Publicado: (2022)

Assessment of a multi-cytokine profile by a novel biochip-based assay allows correlation of cytokine profiles with clinical outcomes in adult recipients of umbilical cord blood transplantation
por: Karantanos, Theodoros, et al.
Publicado: (2019)

Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active
por: Garcia, Jacqueline S., et al.
Publicado: (2021)

Allogeneic Transplantation for Chronic Lymphocytic Leukemia
por: Laurenti, Luca, et al.
Publicado: (2010)

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation
por: Penter, Livius, et al.
Publicado: (2021)

Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse
por: Shapiro, Roman M., et al.
Publicado: (2022)

Multicenter Validation Study of a Transplantation-Specific Cytogenetics Grouping Scheme for Patients with Myelodysplastic Syndromes
por: Armand, Philippe, et al.
Publicado: (2009)

Oral epithelial dysplasia and squamous cell carcinoma following allogeneic hematopoietic stem cell transplantation: clinical presentation and treatment outcomes
por: Mawardi, Hani, et al.
Publicado: (2011)

Impact of COVID-19 Pandemic on Hematopoietic Stem Cell Transplantation (HSCT) and Immune Effector Cell (IEC) Therapies: A Large US Cancer Center Experience
por: Maurer, Katie, et al.
Publicado: (2021)

Molecular assessment and the current limits of post-transplant prognostication for chronic myelomonocytic leukemia
por: Gibson, Christopher J., et al.
Publicado: (2022)

Prostaglandin E2 promotes survival of naive UCB T cells via the Wnt/β-catenin pathway and alters immune reconstitution after UCBT
por: Li, L, et al.
Publicado: (2014)

Allogeneic Hematopoietic Cell Transplantation in the Treatment of Chronic Lymphocytic Leukemia: Why and When?
por: Delioukina, Maria L., et al.
Publicado: (2010)

Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience
por: Shadman, Mazyar, et al.
Publicado: (2019)

The role of allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: A review
por: Puckrin, Robert, et al.
Publicado: (2023)

Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy
por: Bachireddy, Pavan, et al.
Publicado: (2023)

Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)
por: Freeman, Ciara L., et al.
Publicado: (2016)

Practical management of tumour lysis syndrome in venetoclax‐treated patients with chronic lymphocytic leukaemia
por: Gribben, John G.
Publicado: (2019)

Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome
por: Dillon, Laura W., et al.
Publicado: (2021)

Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease
por: Wobma, Holly, et al.
Publicado: (2023)

Long-term health outcomes of allogeneic hematopoietic stem cell transplantation
por: Kelkar, Amar H., et al.
Publicado: (2023)

Evaluation of allogeneic and autologous membrane-bound IL-21–expanded NK cells for chronic lymphocytic leukemia therapy
por: Yano, Max, et al.
Publicado: (2022)

MicroRNA Expression Profiling Identifies Activated B Cell Status in Chronic Lymphocytic Leukemia Cells
por: Li, Shuqiang, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ntt7h2h75psio9n0j46hkuq356